The International Workshop on HIV and Hepatitis Observational Databases (hereinafter referred to as “IWHOD” or “the Workshop”) is an annual workshop run to promote both knowledge generation and knowledge transfer in the use of observational databases. The multidisciplinary Workshop, bringing together clinicians, epidemiologists and methodologists, was established 25 years ago to optimize the use of HIV cohort data in research originating primarily from Europe, North America, and Australia. It has since expanded to include cohort research from Africa, Asia, and South and Central America. While originally focusing on HIV, IWHOD has expanded to include presentations using observational data from other research areas related to HIV and infectious diseases where observational methods are used. These include viral hepatitis, other sexually transmitted and blood borne infections, PrEP, TB, and COVID-19 given similar scientific questions and methodologies.

The IWHOD Scientific Committee is responsible for developing the scientific focus and program content for the annual Workshop, selecting speakers and co-chairs, conducting peer review of abstracts submitted and identifying potential funders.

Après une première certification ISO en 2009 et une succession positive de renouvellements, l’année 2024 s’inscrit dans la continuité !
Après deux nouvelles journées très intenses d’audit, les 13 et 14 mai 2024, l’équipe a pu une nouvelle fois démontrer ses qualités, ses compétences et son engagement dans une démarche d’amélioration continue.

Despite the rapid development of various SARS-CoV-2 vaccines, the control of the pandemic is hampered by the constant emergence of SARS-CoV-2 variants escaping vaccine-induced immunity and the waning of immunity. SOLVE will tackle these challenges by deciphering the mechanisms of induction of long-lasting immunity and evaluating new vaccine platforms. To achieve this goal, an integrated plan has been developed including six pillars: 1) Vaccine discovery and design; 2) Head-to-head evaluation of the immune response and long-lasting immunity induced by four vaccine platforms in the preclinical setting; 3) Validation of the pre-clinical results in an experimental medicine trial (EMT); 4) Immune mechanisms of long-lasting immunity; 5) Data Science; 6) Determinants of population adherence to vaccination. New immunogens including key mutations from most recent variants in RBD and Nucleocapsid sequences highly conserved across Sarbecoviruses, will be delivered through: antigen-targeting to dendritic cells (DC), i.e. CD40 DC-targeting, nanoparticles, a MVA vector and 2nd generations of mRNAs. SOLVE will evaluate in depth the immunogenicity of these vaccines in the preclinical setting, and in an EMT testing two vaccines, i.e. CD40 DC-targeting and MVA with available GMP clinical lots. SOLVE will benefit from the most advanced technologies to identify the mechanisms of long-lasting immunity. Integrative analyses of high throughput data, including from large cohorts, will provide insights for identification of factors (demographics, vaccines, immunity) which impact quality and longevity of immunity. SOLVE will investigate stakeholders’s perspective on the acceptability of large vaccination campaigns to improve implementation of next generation of vaccines in a preparedness track. The consortium gathers 8 renowned public/private institutions supported by a governance facilitating fast sharing of information to keep up with a tight schedule imposed by the pandemic.